# A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

> **NCT01844180** · PHASE2 · COMPLETED · sponsor: **Ono Pharma USA Inc** · enrollment: 200 (actual)

## Conditions studied

- Irritable Bowel Syndrome (IBS)

## Interventions

- **DRUG:** ONO-2952
- **DRUG:** ONO-2952 Matching Placebo

## Key facts

- **NCT ID:** NCT01844180
- **Lead sponsor:** Ono Pharma USA Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2014-07
- **Final completion:** —
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844180, "A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01844180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*